DNA RNA and Cells

17 Jul 2018 Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update
17 Jul 2018 Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
17 Jul 2018 MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
16 Jul 2018 ANP initiates ATL1102 Phase II clinical trial in Duchenne Muscular Dystroph
13 Jul 2018 Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC
12 Jul 2018 Moderna Provides Mid-Year Corporate Update
12 Jul 2018 Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union
12 Jul 2018 Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers
10 Jul 2018 PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy
10 Jul 2018 miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
10 Jul 2018 Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial
29 Jun 2018 European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
29 Jun 2018 Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
29 Jun 2018 uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
29 Jun 2018 Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
28 Jun 2018 ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
27 Jun 2018 Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy
21 Jun 2018 TxCell: First In vivo Proof-of-Concept Data with CD8+ CAR-Treg Presented at FOCIS 2018
21 Jun 2018 SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab
19 Jun 2018 Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation
19 Jun 2018 Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrop
19 Jun 2018 Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001
19 Jun 2018 Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
17 Jun 2018 Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15 Jun 2018 Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up